IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice

Journal of Immunology

Volumn 188, Issue 1, 2012, Pages 462-469

  Van Belle, Astrid B ^a,b   De Heusch, Magali ^a,b   Lemaire, Muriel M ^a,b   Hendrickx, Emilie ^a,b   Warnier, Guy ^a,b   Dunussi Joannopoulos, Kyri ^c   Fouser, Lynette A ^c   Renauld, Jean Christophe ^a,b   Dumoutier, Laure ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CD11B ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CXCL3 CHEMOKINE; CYTOKERATIN 14; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 23; LORICRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; PSORIASIN; RAG2 PROTEIN; T LYMPHOCYTE RECEPTOR;

ACANTHOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD5+ T CELL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRANULOCYTE; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; KERATINOCYTE; LYMPH NODE; MOUSE; NEUTROPHIL; NONHUMAN; PARAKERATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PUSTULE; SKIN DEFECT; SKIN EXFOLIATION; SKIN INFLAMMATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIGENS, DIFFERENTIATION; CHEMOKINE CCL3; DERMATITIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; INTERLEUKINS; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NEUTROPHILS; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SKIN; T-LYMPHOCYTES;

EID: 84855367696     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102224     Document Type: Article

References (54)

1. Renauld, J. C. 2003. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3: 667-676.
2. Geboes, L., L. Dumoutier, H. Kelchtermans, E. Schurgers, T. Mitera, J. C. Renauld, and P. Matthys. 2009. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 60: 390-395.
3. Zenewicz, L. A., G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, S. Stevens, and R. A. Flavell. 2008. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29: 947-957.
4. Boniface, K., F. X. Bernard, M. Garcia, A. L. Gurney, J. C. Lecron, and F. Morel. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174: 3695-3702. (Pubitemid 40354080)
5. Boniface, K., E. Guignouard, N. Pedretti, M. Garcia, A. Delwail, F. X. Bernard, F. Nau, G. Guillet, G. Dagregorio, H. Yssel, et al. 2007. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin. Exp. Immunol. 150: 407-415. (Pubitemid 350098734)
6. Wolk, K., S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241-254. (Pubitemid 39094053)
7. Wolk, K., E. Witte, E. Wallace, W. D. Döcke, S. Kunz, K. Asadullah, H. D. Volk, W. Sterry, and R. Sabat. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36: 1309-1323.
8. Liang, S. C., X. Y. Tan, D. P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, M. Collins, and L. A. Fouser. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203: 2271-2279. (Pubitemid 44498362)
9. Eyerich, S., J. Wagener, V. Wenzel, C. Scarponi, D. Pennino, C. Albanesi, M. Schaller, H. Behrendt, J. Ring, C. B. Schmidt-Weber, et al. 2011. IL-22 and TNF-a represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41: 1894-1901.
10. Sabat, R., S. Philipp, C. Höflich, S. Kreutzer, E. Wallace, K. Asadullah, H. D. Volk, W. Sterry, and K. Wolk. 2007. Immunopathogenesis of psoriasis. Exp. Dermatol. 16: 779-798. (Pubitemid 47377643)
11. Caproni, M., E. Antiga, L. Melani, W. Volpi, E. Del Bianco, and P. Fabbri. 2009. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J. Clin. Immunol. 29: 210-214.
12. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130. (Pubitemid 38076484)
13. Lo, Y. H., K. Torii, C. Saito, T. Furuhashi, A. Maeda, and A. Morita. 2010. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J. Dermatol. Sci. 58: 225-227.
14. Haider, A. S., M. A. Lowes, M. Suárez-Fariñas, L. C. Zaba, I. Cardinale, A. Khatcherian, I. Novitskaya, K. M. Wittkowski, and J. G. Krueger. 2008. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J. Immunol. 180: 1913-1920.
15. Gudjonsson, J. E., A. Johnston, M. Dyson, H. Valdimarsson, and J. T. Elder. 2007. Mouse models of psoriasis. J. Invest. Dermatol. 127: 1292-1308. (Pubitemid 46763003)
16. Schön, M. P. 2008. Animal models of psoriasis: a critical appraisal. Exp. Dermatol. 17: 703-712. (Pubitemid 352044366)
17. Nograles, K. E., B. Davidovici, and J. G. Krueger. 2010. New insights in the immunologic basis of psoriasis. Semin. Cutan. Med. Surg. 29: 3-9.
18. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
19. Wolk, K., H. S. Haugen, W. Xu, E. Witte, K. Waggie, M. Anderson, E. Vom Baur, K. Witte, K. Warszawska, S. Philipp, et al. 2009. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-g are not. J. Mol. Med. 87: 523-536.
20. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651. (Pubitemid 46232884)
21. Ma, H. L., S. Liang, J. Li, L. Napierata, T. Brown, S. Benoit, M. Senices, D. Gill, K. Dunussi-Joannopoulos, M. Collins, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607. (Pubitemid 351206549)
22. van der Fits, L., S. Mourits, J. S. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A. M. Mus, E. Florencia, E. P. Prens, and E. Lubberts. 2009. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182: 5836-5845.
23. Beutner, K. R., and A. Ferenczy. 1997. Therapeutic approaches to genital warts. Am. J. Med. 102(5A): 28-37. (Pubitemid 127695957)
24. Geisse, J. K., P. Rich, A. Pandya, K. Gross, K. Andres, A. Ginkel, and M. Owens. 2002. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J. Am. Acad. Dermatol. 47: 390-398.
25. Szeimies, R. M., M. J. Gerritsen, G. Gupta, J. P. Ortonne, S. Serresi, J. Bichel, J. H. Lee, T. L. Fox, and A. Alomar. 2004. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J. Am. Acad. Dermatol. 51: 547-555. (Pubitemid 39278073)
26. Gilliet, M., C. Conrad, M. Geiges, A. Cozzio, W. Thürlimann, G. Burg, F. O. Nestle, and R. Dummer. 2004. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140: 1490-1495. (Pubitemid 39627441)
27. Patel, U., N. M. Mark, B. C. Machler, and V. J. Levine. 2011. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br. J. Dermatol. 164: 670-672.
28. Rajan, N., and J. A. Langtry. 2006. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin. Exp. Dermatol. 31: 140-141.
29. Wu, J. K., G. Siller, and G. Strutton. 2004. Psoriasis induced by topical imiquimod. Australas. J. Dermatol. 45: 47-50. (Pubitemid 38315850)
30. Fanti, P. A., E. Dika, S. Vaccari, C. Miscial, and C. Varotti. 2006. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Dermatol. 45: 1464-1465. (Pubitemid 44869771)
31. Kreymborg, K., R. Etzensperger, L. Dumoutier, S. Haak, A. Rebollo, T. Buch, F. L. Heppner, J. C. Renauld, and B. Becher. 2007. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J. Immunol. 179: 8098-8104.
32. Uyttenhove, C., C. Sommereyns, I. Théate, T. Michiels, and J. Van Snick. 2007. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 1110: 330-336. (Pubitemid 350043022)
33. Nair, R. P., A. Ruether, P. E. Stuart, S. Jenisch, T. Tejasvi, R. Hiremagalore, S. Schreiber, D. Kabelitz, H. W. Lim, J. J. Voorhees, et al. 2008. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J. Invest. Dermatol. 128: 1653-1661. (Pubitemid 351847381)
34. Smith, R. L., R. B. Warren, S. Eyre, P. Ho, X. Ke, H. S. Young, C. E. Griffiths, and J. Worthington. 2008. Polymorphisms in the IL-12b and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J. Invest. Dermatol. 128: 1325-1327. (Pubitemid 351543190)
35. Cargill, M., S. J. Schrodi, M. Chang, V. E. Garcia, R. Brandon, K. P. Callis, N. Matsunami, K. G. Ardlie, D. Civello, J. J. Catanese, et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80: 273-290. (Pubitemid 46175676)
36. Capon, F., P. Di Meglio, J. Szaub, N. J. Prescott, C. Dunster, L. Baumber, K. Timms, A. Gutin, V. Abkevic, A. D. Burden, et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206. (Pubitemid 47241785)
37. Hueber, W., D. D. Patel, T. Dryja, A. M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M. H. Gold, P. Durez, et al. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2: 52ra72.
38. Krueger, G. G., R. G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, L. T. Dooley, M. Lebwohl; CNTO 1275 Psoriasis Study Group. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356: 580-592. (Pubitemid 46220818)
39. Nakajima, K., T. Kanda, M. Takaishi, T. Shiga, K. Miyoshi, H. Nakajima, R. Kamijima, M. Tarutani, J. M. Benson, M. M. Elloso, et al. 2011. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186: 4481-4489.
40. Wolk, K., K. Witte, E. Witte, S. Proesch, G. Schulze-Tanzil, K. Nasilowska, J. Thilo, K. Asadullah, W. Sterry, H. D. Volk, and R. Sabat. 2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc. Biol. 83: 1181-1193.
41. + cells that provide innate mucosal immune defense. Immunity 29: 958-970.
42. + cell populations in gut and skin. Nat. Immunol. 10: 75-82.
43. Colonna, M. 2009. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31: 15-23.
44. + cells. Nat. Immunol. 10: 83-91.
45. + innate murine spleen cells upon inflammatory stimuli and contributes to LPS-induced lethality. Eur. J. Immunol. 41: 1075-1085.
46. + immune cells in spleen and mucosa. J. Immunol. 185: 1177-1185.
47. Nestle, F. O., D. H. Kaplan, and J. Barker. 2009. Psoriasis. N. Engl. J. Med. 361: 496-509.
48. Valdimarsson, H., R. H. Thorleifsdottir, S. L. Sigurdardottir, J. E. Gudjonsson, and A. Johnston. 2009. Psoriasis - as an autoimmune disease caused by molecular mimicry. Trends Immunol. 30: 494-501.
49. Seung, N. R., E. J. Park, C. W. Kim, K. H. Kim, K. J. Kim, H. J. Cho, and H. R. Park. 2007. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gd in plaque and guttate psoriasis. J. Cutan. Pathol. 34: 903-911. (Pubitemid 350132007)
50. Bonneville, M., R. L. O'Brien, and W. K. Born. 2010. gd T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10: 467-478.
51. Ness-Schwickerath, K. J., and C. T. Morita. 2011. Regulation and function of IL-17A- and IL-22-producing gd T cells. Cell. Mol. Life Sci. 68: 2371-2390.
52. de Jong, A., V. Peña-Cruz, T. Y. Cheng, R. A. Clark, I. Van Rhijn, and D. B. Moody. 2010. CD1a-autoreactive T cells are a normal component of the human ab T cell repertoire. Nat. Immunol. 11: 1102-1109.
53. Hedrick, M. N., A. S. Lonsdorf, A. K. Shirakawa, C. C. Richard Lee, F. Liao, S. P. Singh, H. H. Zhang, A. Grinberg, P. E. Love, S. T. Hwang, and J. M. Farber. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J. Clin. Invest. 119: 2317-2329.
54. Toichi, E., T. Tachibana, and F. Furukawa. 2000. Rapid improvement of psoriasis vulgaris during drug-induced agranulocytosis. J. Am. Acad. Dermatol. 43: 391-395. (Pubitemid 30636548)